返回
TYK Medicines, Inc（02410.HK）價格
02410.HK 股價走勢圖
TYK MEDICINES-B (02410.HK)
TYK Medicines, Inc
HK$13.57
0.51%
$0.07
盤中： Jan 19, 15:01:13 HKT
暫無資料Earnings FAQ
02410.HK 最近的每股盈餘與預期相比如何？
TYK Medicines, Inc 02410.HK 上一季度的收入表現如何？
TYK Medicines, Inc 的收入預期是多少？
TYK Medicines, Inc 的盈利品質評分是多少？
TYK Medicines, Inc 何時發布財報？
TYK Medicines, Inc 的預期收益是多少？
TYK Medicines, Inc 是否超出收益預期？
關鍵數據
前收市價
$13.56
開盤價
$13.5
當日範圍
$13.26 - $13.59
52週區間
$12.1 - $46.1
交易量
986.0K
平均成交量
3.3M
每股盈餘 (TTM)
-0.84
股息收益率
--
市值
$5.0B
什麼是 TYK MEDICINES-B？
TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 163 full-time employees. The company went IPO on 2024-08-20. The firm is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.